Magnus Sjogren

List of Publications by Year
in descending order

117 papers	8,727 citations	50566 48 h-index	48101 92 g-index
121 all docs	121 docs citations	121 times ranked	11241 citing authors

#	Article	IF	Citations
1	Validating the Danish version of the Eating Disorder Quality of Life Scale (EDQLS) in anorexia nervosa. Eating and Weight Disorders, 2022, , 1.	1.2	0
2	Estimating the Effect of Motivational Interventions in Patients with Eating Disorders: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2022, 12, 577.	1.1	5
3	Anorexia Nervosa: Reduction in Depression during Inpatient Treatment Is Closely Related to Reduction in Eating Disorder Psychopathology. Journal of Personalized Medicine, 2022, 12, 682.	1.1	4
4	BMI at Discharge from Treatment Predicts Relapse in Anorexia Nervosa: A Systematic Scoping Review. Journal of Personalized Medicine, 2022, 12, 836.	1.1	12
5	Treatment studies with cannabinoids in anorexia nervosa: a systematic review. Eating and Weight Disorders, 2021, 26, 407-415.	1.2	11
6	Cognitive improvement following weight gain in patients with anorexia nervosa: A systematic review. European Eating Disorders Review, 2021, 29, 402-426.	2.3	20
7	A Systematic Review and Meta-Analysis Finds Increased Blood Levels of All Forms of Ghrelin in Both Restricting and Binge-Eating/Purging Subtypes of Anorexia Nervosa. Nutrients, 2021, 13, 709.	1.7	19
8	Weight Gain in Adults with Avoidant/Restrictive Food Intake Disorder Compared to Restrictive Anorexia Nervosaâ€"Pilot Findings from a Longitudinal Study. Nutrients, 2021, 13, 871.	1.7	7
9	Cognitive Function in Adults with Enduring Anorexia Nervosa. Nutrients, 2021, 13, 859.	1.7	12
10	Explanatory Factors for Disease-Specific Health-Related Quality of Life in Women with Anorexia Nervosa. Journal of Clinical Medicine, 2021, 10, 1592.	1.0	4
11	Dialectical Behaviour Therapy Improves Emotion Dysregulation Mainly in Binge Eating Disorder and Bulimia Nervosa: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2021, 11, 931.	1.1	20
12	Inpatient Weight Restoration Treatment Is Associated with Decrease in Post-Meal Anxiety. Journal of Personalized Medicine, 2021, 11, 1079.	1.1	6
13	Why Do Women with Eating Disorders Decline Treatment? A Qualitative Study of Barriers to Specialized Eating Disorder Treatment. Nutrients, 2021, 13, 4033.	1.7	3
14	Study protocol of comprehensive risk evaluation for anorexia nervosa in twins (CREAT): a study of discordant monozygotic twins with anorexia nervosa. BMC Psychiatry, 2020, 20, 507.	1.1	6
15	Comorbid depression as a negative predictor of weight gain during treatment of anorexia nervosa: A systematic scoping review. European Eating Disorders Review, 2020, 28, 605-619.	2.3	30
16	Potential shortcomings in current studies on the effect of intranasal oxytocin in Anorexia Nervosa and healthy controls - A systematic review and meta-analysis. Psychopharmacology, 2020, 237, 2891-2903.	1.5	5
17	Case report: cognitive performance in an extreme case of anorexia nervosa with a body mass index of 7.7. BMC Psychiatry, 2020, 20, 284.	1.1	5
18	Sexual function and dysfunction among women with anorexia nervosa: A systematic scoping review. International Journal of Eating Disorders, 2020, 53, 1377-1399.	2.1	12

#	Article	IF	Citations
19	Increased lipid and lipoprotein concentrations in anorexia nervosa: A systematic review and metaâ€analysis. International Journal of Eating Disorders, 2019, 52, 611-629.	2.1	38
20	Dysbiosis of the Microbiota in Anorexia Nervosa: Pathophysiological Implications. , 2019, , .		0
21	A systematic review of blood-based serotonergic biomarkers in Bulimia Nervosa. Psychiatry Research, 2019, 279, 155-171.	1.7	5
22	On motivation as a Target for Intervention in Anorexia Nervosa. Archives in Neurology & Neuroscience, 2019, 5, .	0.1	1
23	A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine. Eating and Weight Disorders, 2018, 23, 399-418.	1.2	33
24	Anorexia Nervosa and Motivation for Behavioral Change - Can it be Enhanced?. Journal of Psychology & Clinical Psychiatry, 2017, 8, .	0.0	2
25	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-Î² concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimer's Research and Therapy, 2015, 7, 53.	3.0	22
26	Effect of diagnostic criteria on prevalence of frontotemporal dementia in the elderly. Alzheimer's and Dementia, 2015, 11, 425-433.	0.4	8
27	A Brief Review of the Biology of Anorexia Nervosa. Journal of Psychology & Clinical Psychiatry, 2015, 4, .	0.0	0
28	The Diagnostic Work-Up of Eating Disorders. Journal of Psychology & Clinical Psychiatry, 2015, 4, .	0.0	0
29	Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population. Current Alzheimer Research, 2014, 11, 40-46.	0.7	6
30	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. Human Psychopharmacology, 2014, 29, 163-171.	0.7	4
31	The future of bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.4	250
32	Developing novel bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 109-114.	0.4	138
33	Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study. Journal of Alzheimer's Disease, 2013, 35, 611-621.	1.2	18
34	Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. Neuropsychopharmacology, 2012, 37, 1036-1046.	2.8	58
35	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiology of Aging, 2012, 33, 831.e1-831.e9.	1.5	36
36	Evaluation of the Glycine Transporter Inhibitor Org 25935 as Augmentation to Cognitive-Behavioral Therapy for Panic Disorder. Journal of Clinical Psychiatry, 2012, 73, 647-653.	1.1	18

#	Article	IF	Citations
37	Apathy is a prominent neuropsychiatric feature of radiological whiteâ€matter changes in patients with dementia. International Journal of Geriatric Psychiatry, 2010, 25, 588-595.	1.3	50
38	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 124-125.	0.9	8
39	Secular changes in cognitive predictors of dementia and mortality in 70-year-olds. Neurology, 2010, 75, 779-785.	1.5	51
40	The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia. Current Alzheimer Research, 2010, 7, 470-476.	0.7	120
41	Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimerâ€™s Disease in Clinical Practice: An Illustration with 3 Case Reports. Case Reports in Neurology, 2010, 2, 5-11.	0.3	3
42	Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent. European Geriatric Medicine, 2010, 1, 58-63.	1.2	26
43	The use of indexes in the interpretation of cerebrospinal fluid analyses. Neurobiology of Aging, 2010, 31, 1654.	1.5	0
44	Cerebrospinal Fluid Î±-Synuclein Does Not Discriminate Between Dementia Disorders. Journal of Alzheimer's Disease, 2009, 16, 363-369.	1.2	87
45	The pattern of cognitive symptoms predicts time to dementia onset. Alzheimer's and Dementia, 2009, 5, 199-206.	0.4	16
46	Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimerâ€™s Disease Patients and Healthy Individuals. Neurochemical Research, 2008, 33, 1332-1340.	1.6	95
47	Small heat shock proteins Hsp27 or Î±Bâ€crystallin and the protein components of neurofibrillary tangles: Tau and neurofilaments. Journal of Neuroscience Research, 2008, 86, 1343-1352.	1.3	73
48	Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. Current Opinion in Psychiatry, 2008, 21, 555-561.	3.1	41
49	Low Serum Potassium in Mid Life Associated with Decreased Cerebrospinal Fluid AÎ²42 in Late Life. Alzheimer Disease and Associated Disorders, 2006, 20, 30-36.	0.6	20
50	Frontotemporal dementiaâ€”A brief review. Mechanisms of Ageing and Development, 2006, 127, 180-187.	2.2	23
51	Cholesterol and Alzheimer's diseaseâ€”is there a relation?. Mechanisms of Ageing and Development, 2006, 127, 138-147.	2.2	86
52	Proteome studies of CSF in AD patients. Mechanisms of Ageing and Development, 2006, 127, 133-137.	2.2	40
53	Assessments of the accumulation severities of amyloid Î²-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. Neurobiology of Disease, 2006, 22, 657-668.	2.1	55
54	Depressive symptoms and white matter changes in patients with dementia. International Journal of Geriatric Psychiatry, 2006, 21, 119-125.	1.3	27

#	Article	IF	Citations
55	Vagus Nerve Stimulation in Patients With Alzheimer's Disease. Journal of Clinical Psychiatry, 2006, 67, 1171-1178.	1.1	165
56	Zinc induces neurofilament phosphorylation independent of p70 S6 kinase in N2a cells. NeuroReport, 2005, 16, 591-595.	0.6	31
57	The Use of Proteomics in Biomarker Discovery in Neurodegenerative Diseases. Disease Markers, 2005, 21, 81-92.	0.6	90
58	The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1485-1490.	0.9	156
59	Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology, 2005, 65, 1894-1900.	1.5	34
60	High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology, 2005, 64, 1689-1695.	1.5	346
61	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 256-265.	0.7	86
62	The link between cholesterol and Alzheimer's disease. World Journal of Biological Psychiatry, 2005, 6, 85-97.	1.3	54
63	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95.	13.8	390
64	Negative Neurofilament Light and Tau Immunostaining in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 17, 346-349.	0.7	3
65	Five-Year Outcome of Cholinergic Treatment of Alzheimerâ€™s Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy. Dementia and Geriatric Cognitive Disorders, 2004, 18, 197-206.	0.7	38
66	Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. Journal of Psychiatric Research, 2004, 38, 113-121.	1.5	161
67	HPA axis activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment?refractory depression. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 349-355.	1.8	27
68	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clinical Biochemistry, 2004, 37, 230-237.	0.8	43
69	Proteomics for drug target discovery. Chemometrics and Intelligent Laboratory Systems, 2004, 73, 47-53.	1.8	18
70	P3-241 Zinc induces phosphorylation of neurofilament proteins in mouse N2A neuroblastoma cells. Neurobiology of Aging, 2004, 25, S423.	1.5	0
71	Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Science, 2004, 2, 7.	0.7	45
72	Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathologica, 2003, 105, 469-476.	3.9	51

#	Article	IF	Citations
73	Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness. Journal of Affective Disorders, 2003, 74, 185-189.	2.0	22
74	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 132-136.	1.3	69
75	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 520-526.	1.3	55
76	Measurement of Î±- and Î²-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology, 2003, 183, 74-80.	2.0	114
77	Advances in the detection of Alzheimer's diseaseâ€"use of cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2003, 332, 1-10.	0.5	57
78	Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. Neuroscience Letters, 2003, 340, 69-73.	1.0	28
79	Classification and Subtypes of Vascular Dementia. International Psychogeriatrics, 2003, 15, 27-37.	0.6	39
80	Treatment with Simvastatin in Patients with Alzheimerâ€™s Disease Lowers Both Î±- and Î²-Cleaved Amyloid Precursor Protein. Dementia and Geriatric Cognitive Disorders, 2003, 16, 25-30.	0.7	102
81	CSF markers for Alzheimer's disease: Total tau, phospho-tau and AÎ²42. World Journal of Biological Psychiatry, 2003, 4, 147-155.	1.3	108
82	Treatment of Aggressive Behavior in Dementia With the Anticonvulsant Topiramate: A Retrospective Pilot Study. International Psychogeriatrics, 2003, 15, 307-309.	0.6	29
83	Objective Measurement of the Alertness Level in Dementia. Dementia and Geriatric Cognitive Disorders, 2003, 15, 212-217.	0.7	7
84	Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2003, 16, 200-207.	0.7	41
85	Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. NeuroReport, 2002, 13, 611-615.	0.6	190
86	Decreased CSF-Î²-Amyloid 42 in Alzheimerâ€™s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of Î²-Amyloid Induced by Disparate Mechanisms. Dementia and Geriatric Cognitive Disorders, 2002, 13, 112-118.	0.7	125
87	Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Molecular Brain Research, 2002, 109, 128-133.	2.5	95
88	Increased intrathecal levels of the angiogenic factors VEGF and TGF-Î² in Alzheimerâ€™s disease and vascular dementia. Neurobiology of Aging, 2002, 23, 237-243.	1.5	329
89	Biological Correlates of Clinical Subgroups of Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2002, 14, 191-197.	0.7	13
90	Relationship between depressive symptomatology and the subcortical brain syndrome in dementia. International Journal of Geriatric Psychiatry, 2002, 17, 774-778.	1.3	17

#	Article	IF	Citations
91	Cognition-Enhancing Effect of Vagus Nerve Stimulation in Patients With Alzheimerâ€™s Disease. Journal of Clinical Psychiatry, 2002, 63, 972-980.	1.1	170
92	Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E Îµ4 Frequency, but No Tau Gene Mutations. Experimental Neurology, 2001, 168, 413-418.	2.0	70
93	Low cerebrospinal fluid Î²-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neuroscience Letters, 2001, 314, 33-36.	1.0	71
94	EDRF transcripts and diagnosis of variant Creutzfeldt-Jakob disease. Lancet, The, 2001, 357, 2069-2070.	6.3	6
95	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimerâ€™s Disease, Reflecting a Common Pathophysiological Process. Dementia and Geriatric Cognitive Disorders, 2001, 12, 257-264.	0.7	102
96	Tacrine and rate of progression in Alzheimer's disease â€“ relation to ApoE allele genotype. Journal of Neural Transmission, 2001, 108, 451-458.	1.4	50
97	The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmologica, 2001, 79, 283-285.	0.4	95
98	Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. Journal of Neuroscience Research, 2001, 66, 510-516.	1.3	175
99	Pathophysiological aspects of frontotemporal dementiaâ€”emphasis on cytoskeleton proteins and autoimmunity. Mechanisms of Ageing and Development, 2001, 122, 1923-1935.	2.2	24
100	Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mechanisms of Ageing and Development, 2001, 122, 1937-1949.	2.2	51
101	Treatment of Alzheimerâ€™s Disease with Clioquinol. Dementia and Geriatric Cognitive Disorders, 2001, 12, 408-414.	0.7	202
102	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. Stroke, 2001, 32, 1318-1322.	1.0	1,506
103	Frontotemporal Dementia Can Be Distinguished from Alzheimerâ€™s Disease and Subcortical White Matter Dementia by an Anterior-to-Posterior rCBF-SPET Ratio. Dementia and Geriatric Cognitive Disorders, 2000, 11, 275-285.	0.7	60
104	Oral d-fenfluramine test in treatment-refractory depression. Journal of Affective Disorders, 2000, 57, 201-208.	2.0	11
105	CSF levels of tau, Î²-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. Journal of Neural Transmission, 2000, 107, 563-579.	1.4	227
106	Frontotemporal dementia - Clinical and pathophysiological aspects. Nordic Journal of Psychiatry, 2000, 54, 149-150.	0.7	0
107	Symptoms, Vascular Risk Factors and Blood-Brain Barrier Function in Relation to CT White-Matter Changes in Dementia. European Neurology, 2000, 44, 229-235.	0.6	85
108	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 2000, 285, 49-52.	1.0	452

#	Article	IF	Citations
109	Decreased monoamine metabolites in frontotemporal dementia and Alzheimerâ€™s disease. Neurobiology of Aging, 1998, 19, 379-384.	1.5	80
110	Longitudinal EEG Findings in Dementia Related to the Parietal Brain Syndrome and the Degree of Dementia. Dementia and Geriatric Cognitive Disorders, 1998, 9, 199-204.	0.7	6
111	The apolipoprotein E Ïµ4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neuroscience Letters, 1997, 226, 65-67.	1.0	55
112	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. International Journal of Geriatric Psychiatry, 1997, 12, 656-661.	1.3	40
113	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. , 1997, 12, 656.		3
114	Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. Journal of Geriatric Psychiatry and Neurology, 1996, 9, 185-199.	1.2	84
115	Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. Biological Psychiatry, 1995, 38, 210-216.	0.7	42
116	Cytosolic free calcium elevation mediates the phagosome-lysosome fusion during phagocytosis in human neutrophils.. Journal of Cell Biology, 1990, 110, 1555-1564.	2.3	235
117	Cortisol, Depression, and Anxiety Levels Before and After Short-Term Intensive Nutritional Stabilization in Patients With Severe Anorexia Nervosa. Frontiers in Psychiatry, 0, 13, .	1.3	5